Myeloproliferative Disorders

We provide expert care in diagnosing and treating people with myeloproliferative disorders—rare conditions in which the bone marrow does not function properly and makes too many blood cells. Our specialists use advanced testing to identify these chronic, often lifelong conditions that can be difficult to diagnose. Based on your individual needs, we create a comprehensive, long-term treatment plan that includes support services, such as rehabilitation, counseling, and integrative health therapies.

Clinical Trials and Research Studies

Phase 1

A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Learn More

Phase 3

A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Learn More

Phase 2

AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Learn More

Phase 2

A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB ABATACEPT AND SHORT-DURATION TACROLIMUS FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

Learn More